The Feng et al. study reports the case of a patient with advanced cholangiocarcinoma treated with a cocktail of chimeric antigen receptor (CAR)-modified T cells targeting both EGFR and CD133 [168]. The gene discussed is PROM1; the disease is cholangiocarcinoma.